Clinical Trials Logo

Effect of Drug clinical trials

View clinical trials related to Effect of Drug.

Filter by:

NCT ID: NCT06432309 Completed - Parkinson Disease Clinical Trials

Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease

OPAILEC
Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Levodopa-Carbidopa intestinal gel (LCIG) is an effective therapy for complicated Parkinson's disease (PD). Few studies have explored the efficacy and safety of the potential combination of LCIG with catechol-O-methyltransferase (COMT) inhibitors, particularly Opicapone (OPC).

NCT ID: NCT06414018 Not yet recruiting - Effect of Drug Clinical Trials

Effect of Equivalent Dose Sufentanil and Afentanil in Bronchoscopic Treatment

EOEDSAAIBT
Start date: May 20, 2024
Phase: N/A
Study type: Interventional

The equivalent dose of sufentanil and afentanil combined with laryngeal mask was used for complex bronchoscopy to observe the intraoperative effect and the influence on the recovery of patients

NCT ID: NCT06342921 Recruiting - Safety Issues Clinical Trials

ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection

ADC
Start date: December 7, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this Phase II/III study is to investigate the safty and efficacy of ADC189 tablets in adolescents and adults with influenza A virus infection/influenza B virus infection. The main aim to answer: - Phase II study is to evaluate the efficacy of ADC189 tablets in the treatment of adult influenza subjects and determine the optimal therapeutic dose by analyzing the time of virus titer turning to negative. All the results will be used to design the Phase III study. - Phase III study is to evaluate the efficacy of ADC189 tablets by analyzing the duration of remission of all influenza symptoms in adolescents and adults subjects with influenza. Participants will be taken ADC189 teblets/Placebo once, and be observed by 22 days. Phase II study has 3 groups: 15 mg ADC189; 45 mg ADC189; and Placebo; Phase III study has 2 groups: 45 mg ADC189; and Placebo.

NCT ID: NCT06333145 Recruiting - Effect of Drug Clinical Trials

ED90 of Remimazolam Anesthesia Induction in Drug-induced Sleep Endoscopy in Adults

Start date: February 4, 2024
Phase: Phase 4
Study type: Interventional

Exploring the ED90 of remimazolam in Drug-induced Sleep Endoscopy in adults at different BMI groups.

NCT ID: NCT06290219 Not yet recruiting - Effect of Drug Clinical Trials

The Effect of Platelet-rich Plasma Nasal Injection in the Treatment of Traumatic Olfactory Dysfunction

PRP
Start date: March 20, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to explore the efficacy of injecting high-concentration platelet plasma combined with hyaluronic acid into the nasal olfactory mucosa in the treatment of traumatic anosmia.

NCT ID: NCT06197295 Recruiting - Clinical trials for Urinary Bladder, Overactive

Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity

Start date: June 16, 2022
Phase: Phase 4
Study type: Interventional

To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.

NCT ID: NCT06164821 Recruiting - Effect of Drug Clinical Trials

Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

To assesse the efficacy and safety of luspatercept versus placebo in China patients with transfusion-dependent β-thalassaemia.

NCT ID: NCT06141096 Recruiting - Safety Issues Clinical Trials

MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma

MB07133
Start date: January 17, 2020
Phase: Phase 2
Study type: Interventional

A randomized, open, multicenter clinical trial design was adopted, planned to be conducted in three stages, with 91 participants expected to be included in the study to evaluate the efficacy, tolerance, and safety of different doses of MB07133 in the treatment of unresectable advanced primary liver cancer.

NCT ID: NCT06114758 Active, not recruiting - Clinical trials for Postoperative Complications

Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy

Start date: September 1, 2023
Phase:
Study type: Observational [Patient Registry]

Fibroids are the most commonly encountered tumors in the female reproductive system. In patients, fibroids most often lead to abnormal uterine bleeding and the resulting anemia. In some cases, they can cause infertility or habitual abortions. Another complaint caused by fibroids is pain due to pressure and effects on adjacent organs. Very large fibroids can lead to abdominal swelling. Therefore, if a patient becomes symptomatic due to fibroids, myomectomy or, if necessary, hysterectomy is required. Because fibroids have a significant blood supply, there is a high risk of intraoperative bleeding and related complications. Additionally, the most common complication in these patients after the operation is bleeding. In many of these patients, intraoperative or postoperative blood transfusions are performed. If bleeding cannot be intervened early in these patients, hemodynamic instability, shock, coagulopathy, and, in the final stage, death can occur due to hemorrhage. Therefore, both intraoperative and postoperative bleeding control is of vital importance in patients undergoing myomectomy.

NCT ID: NCT06114641 Recruiting - Safety Issues Clinical Trials

Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation Acute Coronary Syndrome (NSTEACS) Patients: a Multicenter, Non-randomized, Open-label, Non-inferiority Trial

Start date: June 1, 2023
Phase: Phase 4
Study type: Interventional

The aim of this study is evaluating safety and effectiveness of Ovine Enoxaparin Sodium in Non-ST-Segment Elevation Acute Coronary Syndrome (NSTEACS) Patients